Effects of cisapride on gall bladder emptying, intestinal transit, and serum deoxycholate: a prospective, randomised, double blind, placebo controlled trial

M J Veysey, P Malcolm, A I Mallet, P J Jenkins, G M Besser, G M Murphy, R H Dowling

Abstract

Background—Octreotide inhibits gall bladder emptying and prolongs intestinal transit. This leads to increases in the proportion of deoxycholic acid in, and cholesterol saturation of, gall bladder bile, factors that contribute to the pathogenesis of octreotide induced gall stones.

Aims—To see if an intestinal prokinetic, cisapride, could overcome these adverse effects of octreotide and if so, be considered as a candidate prophylactic drug for preventing iatrogenic gall bladder stones.

Methods—A randomised, double blind, placebo controlled, crossover design was used to examine the effects of cisapride (10 mg four times daily) on gall bladder emptying, mouth to caecum and large bowel transit times, and the proportions of deoxycholic acid and other bile acids, in fasting serum from: (i) control subjects (n=6), (ii) acromegalic patients not treated with octreotide (n=6), (iii) acromegalic patients on long term octreotide (n=8), and (iv) patients with constipation (n=8).

Results—Cisapride had no prokinetic effect on the gall bladder. In fact, it significantly increased both fasting and postprandial gall bladder volumes. However, it shortened mouth to caecum (from 176 (13) to 113 (11) minutes; p<0.001) and large bowel (from 50 (3.0) to 31 (3.4) h; p<0.001) transit times. It also reduced the proportion of deoxycholic acid in serum from 26 (2.3) to 15 (1.8)% (p<0.001), with a reciprocal increase in the proportion of cholic acid from 40 (3.5) to 51 (3.8)% (p<0.001). There were significant linear relationships between large bowel transit time and the proportions of deoxycholic acid (r=0.81; p<0.001) and cholic acid (r=−0.53; p<0.001) in fasting serum.

Interpretation/summary—Cisapride failed to overcome the adverse effects of octreotide on gall bladder emptying but it countered octreotide induced prolongation of small and large bowel transit. Therefore, if changes in intestinal transit contribute to the development of octreotide induced gall bladder stones, enterokinetcs such as cisapride may prevent their formation.

(Gut 2001;49:828–834)

Keywords: cisapride; deoxycholic acid; octreotide; acromegaly; gall bladder stones; large bowel transit time

Octreotide (OT) is a long acting analogue of somatostatin. It is an effective therapy for acromegaly but after one to two years of OT treatment approximately 30% of patients develop gall bladder stones.1–3

The pathogenesis of OT induced stones is multifactorial. OT not only impairs meal stimulated gall bladder emptying,4 it also prolongs both small4 7 8 and large bowel transit.9 This prolongation of colonic transit leads to increased proportions of deoxycholic acid (DCA) in gall bladder bile10 and in fasting serum11 which in turn are associated with: (i) hypersecretion of biliary cholesterol,12 (ii) partitioning of excess biliary cholesterol into vesicles, (iii) a high vesicular cholesterol/phospholipid molar ratio, and (iv) abnormally rapid nucleation of cholesterol microcrystals.12

The precedent that gall stones might be prevented by the use of prokinetic drugs comes from studies of patients receiving total parenteral nutrition (TPN). During TPN, there is impaired gall bladder emptying,13 14 relative stasis of bile acids within the enterohepatic circulation,15 and an increased incidence of gall bladder sludge and stone formation.16 17 However, in the short term, parenteral injections of cholecystokinin (CCK) (which is prokinetic to both the gall bladder18 and the intestine19) inhibit sludge and stone formation.20

When the present study was designed, we considered using several possible prokinetic regimens but in the end opted for cisapride. Although it was licensed for the treatment of gastro-oesophageal reflux,22 it was also known to shorten both small and large bowel transit times23 24 and, allegedly, to increase gall bladder motility.25 26 We chose it as a prototypic prokinetic agent knowing that alternative “colon specific” prokinetics, such as prucalopride and tegaserod, were under development.27 28

The aims of this study therefore were to determine whether cisapride could overcome the adverse effects of long term OT on meal stimulated gall bladder emptying and on small and large bowel transit. We also wished to see if cisapride could prevent the increase in the proportion of DCA in fasting serum (and by implication in bile) and therefore the attendant risk of gall bladder stone formation.

Abbreviations used in this paper: CCK, cholecystokinin; DCA, deoxycholic acid; 5-HT, 5-hydroxytryptamine; LBTT, large bowel transit time; MCTT, mouth to caecum transit time; OT, octreotide; TPN, total parenteral nutrition.
Subjects and methods

STUDY DESIGN
We used a randomised, double blind, crossover design to investigate the effects of either cisapride, in an oral dose of 10 mg four times a day for two weeks, or placebo on meal stimulated gall bladder emptying, small and large bowel transit, and the proportions of the major bile acids in fasting serum. There was a 14 day “washout” period between the two phases of the study. Participants attended hospital at the end of each two week period when tablets were counted to monitor compliance in taking the prescribed “medication”.

SUBJECTS
There were four unmatched groups of individuals: group 1, six members of the laboratory staff who served as non-acromegalic control subjects (mean age 38 (SEM) 5.5 years (range 28–64); three women); group 2, six patients with acromegaly not treated with OT (mean age 53 (7.8) years (range 28–64); three women). The clinical diagnosis of acromegaly was confirmed by standard criteria; group 3, eight patients with confirmed acromegaly (mean age 42 (5.9) years (range 21–58); four women) treated for 3–48 (median 12) months with 300–600 µg OT/day by subcutaneous injection; and group 4, eight non-acromegalic patients (mean age 43 (6.2) years (range 28–73); seven women) with a clinical diagnosis of idiopathic constipation. These individuals were recruited from the outpatient clinic at Guy’s Hospital.

All 28 individuals had normal liver function tests and none had known intestinal disease. All were gall stone free, as judged by ultrasound. None had taken antibiotics or laxatives within four weeks of serum sampling (see below).

METHODS
We used established protocols to measure meal stimulated gall bladder emptying and small and large bowel transit times.

In brief, after an overnight fast, 10 ml of blood were drawn from which serum was harvested and stored at −20°C until analysed. Patients then consumed a fat rich liquid test meal (250 ml “Ensure”) together with 20 ml of lactulose (substrate for breath hydrogen). Gall bladder emptying was assessed by ultrasound using the ellipsoid method. Volume measurements were taken 30 minutes and immediately before the test meal, and every 15 minutes thereafter until gall bladder volume had returned to its pre-meal value or for a maximum of 90 minutes. All observations were made in triplicate by an experienced radiologist (PM). The following parameters of gall bladder emptying were calculated: (i) fasting volume (FV)—gall bladder volume immediately before the test meal, (ii) residual volume (RV)—minimum gall bladder volume after ingestion of the test meal, (iii) delta volume (DV) or change in gall bladder volume in response to the test meal (FV−RV), (iv) ejection fraction—DV expressed as a percentage of FV, and (v) rate of gall bladder emptying—DV divided by the time needed to reach RV.

Mouth to caecum transit time (MCTT) was measured using the lactulose breath hydrogen technique. End expiratory breath samples were collected in a 20 ml plastic syringe 30 minutes and immediately before the test meal, and every 15 minutes thereafter, either until there was a late peak of breath hydrogen (a rise of greater than 10 ppm above baseline on two consecutive occasions) or until 300 minutes after meal ingestion, at which time measurements were abandoned.

Large bowel transit time (LBTT) was assessed by recording the progress of radio-opaque marker shapes through the intestine. On three successive mornings, subjects ingested a single gelatine capsule containing 20 radio-opaque marker shapes, at 9.00 am. Subjects were asked to eat normally over the three day period, and to maintain their usual pattern of defecation. On day 4, a plain abdominal radiograph was taken, again at approximately 9.00 am, and from this mean total colonic transit time was calculated, as described by Metcalf and colleagues.

Ethical Considerations
The study was approved by the East London and the City Health Authority Research Ethics Committee and by the Lewisham and North Southwark Committee on Ethical Practice. All 28 participants gave written informed consent before the study.

Statistical Analyses
The statistical significance of differences in results between patient groups, and in paired studies, was tested with the non-parametric t test. Univariate regression analyses were performed using Excel software version 5.0 (Microsoft Corporation, 1 Microsoft Way, Redmond, WA 98052-6399, USA). Values of p<0.05 were considered to be statistically significant. Unless otherwise stated, results are given as mean (SEM) and range.

Results
All 28 individuals completed the study without difficulty and none reported significant side effects during either the placebo or cisapride treatment periods.
Table 1  Group data for meal stimulated gall bladder emptying

<table>
<thead>
<tr>
<th></th>
<th>Non-acromegalic control subjects (n=6)</th>
<th>Acromegalic patients</th>
<th>Patients with simple constipation (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Cisapride</td>
<td>Placebo</td>
</tr>
<tr>
<td>Fasting volume (ml)</td>
<td>21 (3.1)</td>
<td>36 (7.4)a</td>
<td>33 (6.2)</td>
</tr>
<tr>
<td>Residual volume (ml)</td>
<td>4.7 (0.6)</td>
<td>9.7 (2.0)</td>
<td>9.4 (1.8)</td>
</tr>
<tr>
<td>Delta volume (ml)</td>
<td>16 (3.3)</td>
<td>26 (5.5)</td>
<td>24 (4.7)</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>75 (5.0)</td>
<td>72 (2.7)</td>
<td>70 (4.1)</td>
</tr>
<tr>
<td>Rate of gall bladder emptying (ml/min)</td>
<td>0.47 (0.1)</td>
<td>0.79 (0.2)</td>
<td>0.59 (0.1)</td>
</tr>
</tbody>
</table>

Results are mean (SEM). Unless otherwise indicated, differences between means were not statistically significant: a p<0.001, b p<0.01, c p<0.05 versus placebo.

GALL BLADDER EMPTYING

In non-acromegalic control subjects, both fasting and residual gall bladder volumes were greater during cisapride treatment than during placebo (p<0.05). However, the 5-hydroxytryptamine (5-HT4) agonist had no significant effect on delta volume, ejection fraction, or rate of gall bladder emptying (table 1).

In acromegalic patients not treated with OT, there was a similar pattern of results except that before treatment (that is, while taking placebo), fasting and residual volumes were significantly higher (p<0.05) than those in non-acromegalic controls. Moreover, during cisapride, delta volume was significantly greater than that found when patients were taking placebo.

In acromegalic patients treated with long term OT and in patients with simple constipation, fasting, residual, and delta gall bladder volumes were significantly greater, and the rate of gall bladder emptying significantly more rapid, during cisapride treatment than during placebo. Again, there were no significant differences in ejection fractions during placebo and cisapride treatments. However, during long term OT, the ejection fraction was markedly reduced compared with that in the other three groups.

MOUTH TO CAECUM TRANSIT TIME (MCTT)

As the results in fig 1 show, cisapride consistently and significantly reduced MCTT, which decreased from a mean value of 176 (13) minutes while subjects were taking placebo to 113 (11) minutes during treatment with cisapride (p<0.001). This prokinetic effect was seen in all four groups, the per cent reduction in mean MCTTs ranging from 30% to 42% (table 2).

LARGE BOWEL TRANSIT TIME (LBTT)

The pattern of results for LBTT was broadly similar to that for MCTT. Indeed, with one exception (a control subject who showed little difference in colonic transit between the placebo and cisapride treatments), pooled data for all four groups (fig 2) showed that the 5-HT4 agonist had a consistent effect on LBTT, with a mean acceleration of 19 hours (p<0.001). As the data in table 2 show, the mean reductions in LBTT during treatment with cisapride ranged from 30% in the constipated patients to 56% in the non-acromegalic controls. In fact, the greatest difference was in acromegalic patients on long term OT in whom the addition of cisapride shortened the mean colonic transit time by 24 hours.

FASTING SERUM BILE ACID COMPOSITION

As the results in fig 3 show, cisapride not only accelerated transit through both the small and large intestine, it also resulted in a 42% reduction in the mean proportion of DCA in fasting serum which fell from 26 (2.3)% of total serum bile acids with placebo to 15 (1.8)% after two weeks of cisapride (p<0.001). As indicated in table 3, the decrease in the mean proportion of serum DCA seen during

Table 2  Group data for mouth to caecum and large bowel transit times

<table>
<thead>
<tr>
<th></th>
<th>Non-acromegalic control subjects (n=6)</th>
<th>Acromegalic patients</th>
<th>Patients with simple constipation (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Cisapride</td>
<td>Placebo</td>
</tr>
<tr>
<td>MCTT (min)</td>
<td>120 (13)</td>
<td>70 (7.4)a</td>
<td>163 (9.8)</td>
</tr>
<tr>
<td>LBTT (h)</td>
<td>27 (2.9)</td>
<td>12 (2.9)y</td>
<td>21 (5.8)</td>
</tr>
</tbody>
</table>

Results are mean (SEM). Unless otherwise indicated, differences between means were not statistically significant: a p<0.001, b p<0.01, c p<0.05 versus placebo.

OT, octreotide; LTOT, long term octreotide; MCTT, mouth to caecum transit time; LBTT, large bowl transit time.
treatment with the 5-HT₄ agonist ranged from just under 30% in acromegalic patients not treated with OT to 50% in those receiving long term OT. In fact, the mean reductions in the proportion of DCA were statistically significant in all four groups (p<0.01). As the results in table 3 also show, cisapride induced a reciprocal increase in the mean proportion of the “parent” bile acid, cholic acid, in all four groups. Although none of the increases in the mean per cent cholic acid in serum in the subgroups was statistically significant, when the data for all 28 individuals were pooled, the increase (from 40 (3.5)% during placebo to 51 (3.8)% during cisapride) was significant (p<0.01). There were no significant changes in the proportions of either chenodeoxycholic acid or ursodeoxycholic acid during cisapride therapy compared with those seen during placebo treatment.

RELATIONSHIPS BETWEEN INTESTINAL TRANSIT AND SERUM BILE ACID COMPOSITION
The relationship between LBTT and the proportion of DCA in fasting serum (expressed as a percentage of total serum bile acids) is plotted in fig 4 (n=56; two observations in each of the 28 subjects). Results for the univariate analyses, relating both MCTT and LBTT to the proportions of the major individual bile acids in serum (including DCA), are given in table 4.

As indicated in both fig 4 and table 4, there was a positive linear relationship between LBTT and the proportion of DCA in fasting serum ($r=0.81; p<0.001$). At the same time, there was a weaker ($r=-0.53$) but still significant (p<0.01) negative relationship between LBTT and the proportion of cholic acid in serum. However, the correlation coefficients between LBTT and the proportions of the other serum bile acids were low, and not statistically significant, as were the plots relating

Table 3  Group data for serum bile acid composition

<table>
<thead>
<tr>
<th></th>
<th>Non-acromegalic control subjects (n=6)</th>
<th>Not treated with OT (n=6)</th>
<th>Treated with LTOT (n=8)</th>
<th>Patients with simple constipation (n=8)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>Cisapride</td>
<td>Placebo</td>
<td>Cisapride</td>
</tr>
<tr>
<td>CA</td>
<td>53 (8.9)</td>
<td>61 (8.9)</td>
<td>34 (4.7)</td>
<td>50 (6.5)</td>
</tr>
<tr>
<td>DCA</td>
<td>16 (1.3)</td>
<td>8.8 (2.2)</td>
<td>24 (4.1)</td>
<td>17 (3.0)</td>
</tr>
<tr>
<td>CDCA</td>
<td>30 (7.9)</td>
<td>27 (7.4)</td>
<td>38 (7.6)</td>
<td>30 (5.9)</td>
</tr>
<tr>
<td>UDCA</td>
<td>2.4 (0.7)</td>
<td>2.7 (0.6)</td>
<td>3.5 (1.0)</td>
<td>2.6 (0.7)</td>
</tr>
</tbody>
</table>

Results are mean (SEM).

Unless otherwise indicated, differences between means were not statistically significant: *p<0.001, †p<0.01 versus placebo. OT, octreotide; LTOT, long term octreotide; CA, cholic acid; DCA, deoxycholic acid; CDCA, chenodeoxycholic acid; UDCA, ursodeoxycholic acid.

Figure 2  Paired data (individual data points with means) for large bowel transit time (LBTT) in non-acromegalic control subjects (n=6), acromegalic patients not treated with octreotide (n=6), acromegalic patients on long term octreotide treatment (n=8), and patients with simple constipation (n=8), receiving placebo or cisapride (see text).

Figure 3  Paired data (individual data points with means) for the proportion of deoxycholic acid (DCA), expressed as a percentage of total serum bile acids in non-acromegalic control subjects (n=6), acromegalic patients not treated with octreotide (n=6), acromegalic patients on long term octreotide treatment (n=8), and patients with simple constipation (n=8), receiving placebo or cisapride (see text).

Figure 4  (A) Relationship between the proportion of deoxycholic acid (DCA) in fasting serum, expressed as a percentage of total bile acids, and large bowel transit time (LBTT). (B) Relationship between the proportion of cholic acid (CA) in fasting serum, expressed as a percentage of total bile acids, and LBTT.
Variable. In some studies it is high while in others, such as ursodeoxycholic acid, the concordance between bile acid pools in serum and bile, one gate markers for the percentage of bile acids in fasting serum and used them as surro-
measured the proportions of the various bile acids in serum, not only in acromegalic patients—without impairing gall bladder emptying, even if gall bladder emptying remained normal. If this iatrogenic gall bladder stasis is important in gall stone formation, in theory, chronic use of cisapride could increase the risk of gall stone formation—in much the same way that vagotomy promotes gall bladder stasis and increases the incidence of gall stones—without impairing gall bladder emptying.40–42

STUDY DESIGN
Most previous reports of bile acid composition in humans have been based on samples of either gall bladder bile or bile rich duodenal fluid.42 In the present study however we measured the proportions of the various bile acids in fasting serum and used them as surrogate markers for the percentage of bile acids in bile. Although there is a dynamic relationship between bile acid pools in serum and bile, one cannot assume that the proportions of bile acids in fasting serum are necessarily comparable with those in bile. None the less, this is the rationale for using serum sampling to measure circulating bile acids to more intestinal bacteria. In practice however cisapride had no such stimulatory effect on the gall bladder.

In theory, this functional exclusion of the gall bladder might displace the bile acid pool, enhance the enterohepatic cycling rate, expose circulating bile acids to more intestinal bacte-
rrial bile acid metabolising enzyme pathways, and increase the per cent DCA in serum and bile. In practice however cisapride reduced rather than increased per cent DCA in serum, suggesting that its effects on the intestine are more important than those on the gall bladder, in terms of DCA metabolism.

Table 4 Univariate analyses

<table>
<thead>
<tr>
<th></th>
<th>MCTT</th>
<th></th>
<th>LBTT</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>r</td>
<td>p Value</td>
<td>r</td>
<td>p Value</td>
</tr>
<tr>
<td>CA</td>
<td>0.07</td>
<td>NS</td>
<td>-0.53</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>DCA</td>
<td>0.04</td>
<td>NS</td>
<td>0.81</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>CDCA</td>
<td>-0.11</td>
<td>NS</td>
<td>0.02</td>
<td>NS</td>
</tr>
<tr>
<td>UDCA</td>
<td>-0.03</td>
<td>NS</td>
<td>0.05</td>
<td>NS</td>
</tr>
</tbody>
</table>

Correlation coefficients (r) for plots of large bowel transit time (LBTT) and mouth to caecum transit time (MCTT) versus cirrhosis.

and in disease states such as primary biliary cirrhosis.45

When considering which prokinetic agent to use, we explored several possibilities, including lactulose,48 senna,50 high fibre diets,51 erythromycin,52 53 and non-antibiotic analogues of erythromycin,54 all of which have been shown previously to alter intestinal transit and/or bile acid composition. In the end, we opted for cis-
apride as, apart from the non-antibiotic erythromycin analogues (which were not available commercially), it was the only enterokinetic with no known antibiotic properties and no direct effects on bacterial enzyme activities or colonic luminal pH.52

At that time, cisapride had been used extensi-
vately in the treatment of gastro-oesophageal reflux disease. Subsequently, however, con-
cerns were raised about its safety, particularly in relation to its cardiac toxicity, the risk of prolonged QT intervals, and torsade de Pointes arrhythmias.55 56 For this reason, it was subsequently withdrawn from the market in the USA, Britain, and elsewhere.

None the less, the importance of the present observations depends not so much on the choice of individual drug (cisapride) but more on the demonstration that an enterokinetic agent can counter the adverse effects of OT on intestinal transit and induce changes in bile acid composition. Indeed, as noted above, we opted for cisapride in the knowledge that alternative intestinal prokinetic drugs, prucalopride and tegaserod, were under development. These “colon specific” 5-HT4 agonists are effective in accelerating transit through the colon.28–30 Therefore, provided that they are free from significant side effects, either would be preferable to cisapride as the drug of choice in prospective trials of the efficacy of enterokinetics in preventing cholelithiasis.

CISAPRIDE AND GALL BLADDER EMPTYING
Our results, showing that in all four groups mean fasting and residual (postprandial) gall bladder volumes were increased by cisapride, are in agreement with those of some57–59 but not all26 27 investigators. The explanation for this variable pattern of results is unknown but may be due to differences in study design and patient selection. A prokinetic effect of the 5-HT4 agonist on the gall bladder has been claimed in animals57–59 and in dyspeptic patients with impaired gall bladder emptying given a single dose.50 In healthy controls57 58 and in patients who underwent extracorporeal shock-wave lithotripsy treatment for gall stone disease,59 cisapride had no such stimulatory effect on the gall bladder.
CISAPRIDE, INTESTINAL TRANSIT, AND DEOXYCHOLIC ACID

The effects of cisapride on small and large bowel transit were more consistent and less controversial than those described above for the gall bladder. Thus most investigators agree that cisapride accelerates MCTT, not only in control subjects but also in patients with diabetes mellitus, spinal cord injury, and chronic intestinal pseudo-obstruction, all of whom have prolonged oro-cacoal transit. Cisapride also reduces colonic transit in control subjects and in patients with idiopathic constipation, Parkinson’s disease, diabetes mellitus, postoperative ileus, and spinal cord injury. Our data, in acromegalic patients treated and not treated with OT, in constipated patients, and in control subjects, support these findings.

As discussed above, the highly significant linear relationship between per cent DCA in fasting serum and LBTT suggests that the reduction in the proportion of this bile acid in serum during cisapride treatment is mediated through its prokinetic effect on the colon. However, a positive linear correlation can never prove a cause and effect relationship. None the less, the present results confirm and extend those of our previous study in 64 different individuals in whom we also found a significant linear relationship (r=0.76; p<0.001) between the two variables. Taken together, the results of these two studies add to the growing body of evidence that changes in intestinal transit may play an important role in the pathogenesis of cholesterol gall stone disease and that they do so by influencing the metabolism of DCA.

The mechanisms whereby alterations in intestinal transit influence the proportion of DCA in serum and bile are probably multifactorial. Berr and colleagues have shown that there is a relationship between pool size and the formation rate of DCA, and both the quantity of 7α-dehydroxylating bacteria and the activity of the 7α-dehydroxylase enzyme in faeces. In a previous study, we found that compared with stone free controls, patients with cholesterol gall stones had prolonged LBTTs and increased proportions of DCA in fasting serum. We also found that gall stone carriers had more Gram positive anaerobes and increased activities of the 7α-dehydroxylase enzyme in their caecal aspirates than controls. Changes in intestinal transit also induce changes in colonic luminal and/or faecal pH. Thus slow colonic transit is associated with an increase in faecal pH which in turn increases solubilisation (and, therefore, bioavailability) of newly formed DCA.

PREVENTION OF GALL BLADDER STONES

There are no long term, prospective, controlled trials on the efficacy of intestinal prokinetic regimens in preventing gall stone development in high risk groups. However, the precedent that they might do so is based on results of studies in animals and humans in which gall bladder emptying and/or intestinal transit were manipulated pharmacologically. Thus when Xu and colleagues fed a lithogenic diet to ground squirrels, it provoked slow intestinal transit, impaired gall bladder contractility, and induced supersaturated bile. These effects were overcome by the use of erythromycin and cisapride which also normalised bile acid and bile lipid composition. Similarly, when Marcus and Heaton accelerated intestinal transit with senna, the proportion of DCA in, and the cholesterol saturation of, bile rich duodenal fluid were reduced. Moreover, in patients on short term (two weeks) TPN, Sitzmann et al showed that daily injections of CCK (which stimulate both gall bladder emptying and intestinal transit) prevented the formation of gall bladder sludge and stones. The CCK analogue cerylerted also reduced sludge formation by 95% in surgical intensive care patients.

This work was supported by grants from the Special Trustees of Guy’s Hospital and Sandoz (UK) Ltd. These data were presented in part at meetings of the British Society of Gastroenterology (Gut 1996;39(suppl 1):A8) and the 5th United European Gastroenterology Week (Gut 1996;39(suppl 3):A130 and Gut 1996;39(suppl 3):A103).


